Cargando…
An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
Autores principales: | Findlay, Alison, Turner, Craig, Schilter, Heidi, Deodhar, Mandar, Zhou, Wenbin, Perryman, Lara, Foot, Jonathan, Zahoor, Amna, Yao, Yimin, Hamilton, Ross, Brock, Mary, Raso, Christina, Stolp, Jessica, Galati, Marie, Hamprecht, Dieter, Charlton, Brett, Jarolimek, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571951/ https://www.ncbi.nlm.nih.gov/pubmed/34841699 http://dx.doi.org/10.1002/ctm2.572 |
Ejemplares similares
-
The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis
por: Schilter, Heidi, et al.
Publicado: (2018) -
Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer
por: Chang, Joan, et al.
Publicado: (2017) -
Development of ultrasound bioprobe for biological imaging
por: Shekhawat, Gajendra S., et al.
Publicado: (2017) -
AIEgen-Peptide Bioprobes for the Imaging of Organelles
por: Chen, Bochao, et al.
Publicado: (2022) -
Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
por: Yao, Yimin, et al.
Publicado: (2022)